Terheyden H, Jepsen S, Möller B, Rueger D
Klinik für Mund-, Kiefer-, Gesichtschirurgie, Christian Albrechts Universität zu Kiel.
Laryngorhinootologie. 2001 Jan;80(1):47-51. doi: 10.1055/s-2001-11032.
The purpose of this study was to examine whether the combination of an osteoinductive protein (recombinant human osteogenic protein-(rhOP-1 = bone morphogenetic protein-7) with natural bovine bone mineral (BioOss) would improve ossification and the bone-implant contact (BIC) in a sinus floor augmentation with simultaneous placement of implants.
In this study, the maxillary sinus floors in five miniature pigs were augmented with 3 ml BioOss containing 420 micrograms rhOP-1 on the test side and 3 ml BioOss alone on the control side. At the time of augmentation a titanium implant (ITI) was inserted from a laterocaudal direction.
After 6 months of healing the sites of augmentation were removed and examined in non-decalcified sections by microradiography, fluorescence microscopy of sequentially labelled specimens and by histometry. On both sides, significant amounts of newly formed bone were observed. However, on the test sites, the BIC in the augmented area was 80.0% versus 38.6% on control sites. It can be concluded that the application of bone morphogenetic proteins caused a more rapid and enhanced osseointegration of simultaneously placed implants when compared to the bone substitute alone.
Therefore recombinant human osteogenic protein-1 delivered by natural bone mineral has the potential to become a clinical alternative for autogenous bone grafts in sinus floor augmentation.
本研究的目的是探讨骨诱导蛋白（重组人骨生成蛋白-1 = 骨形态发生蛋白-7）与天然牛骨矿物质（BioOss）联合使用是否会在同期植入种植体的上颌窦底提升术中改善骨化和骨-种植体接触（BIC）。
在本研究中，对5只小型猪的上颌窦底进行处理，试验侧用含420微克重组人骨生成蛋白-1的3毫升BioOss进行提升，对照侧仅用3毫升BioOss。在提升时，从后外侧方向植入一枚钛种植体（ITI）。
愈合6个月后，取出提升部位，通过显微放射照相术、对连续标记标本的荧光显微镜检查和组织计量学在未脱钙切片中进行检查。两侧均观察到大量新形成的骨。然而，在试验部位，提升区域的骨-种植体接触率为80.0%，而对照部位为38.6%。可以得出结论，与单独使用骨替代物相比，应用骨形态发生蛋白可使同期植入的种植体骨结合更快速且增强。
因此，由天然骨矿物质递送的重组人骨生成蛋白-1有潜力成为上颌窦底提升术中自体骨移植的临床替代物。
